Pfizer Presents Phase 3 Prevenar 13 Data

Pfizer Inc.

presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age. The study met all primary and secondary objectives and provides the clinical foundation for the Company's regulatory submission in the European Union (EU) and planned regulatory submissions in the United States (U.S.) and other countries around the world to seek expansion of the use of Prevenar 13 to include adults 18 to 49 years of age. These results were presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Berlin, Germany. Data from this study showed